Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
"... there is no room for complacency, Britain has led many cancer breakthroughs. There can be no excuse for it falling further behind in the fight against [#lungcancer]" @thetimes
Early detection is the key to improving lung cancer survival.
#lungcancerscreening
52% of patients taking the EarlyCDT Lung test in the ECLS trial in Scotland were from the lowest socioeconomic groups which provides us an opportunity to access wider healthcare services thereby reducing healthcare inequalities https://bit.ly/2NeI8ki
"Analysis by Oncimmune, a cancer-testing company, found that 43.2 per cent of [#lungcancer] cases were caught at an early stage in the best performing area of England compared with 16.3 per cent in the worst area." @thetimes
#earlycancerdetection #lungcancerscreening
"Pharmacists could play a huge role in improving cancer survival rates by becoming the first port of call for screenings and referrals, a report has said." https://bit.ly/2NeI8ki #lungcancerscreening #lungcancer #lungscreening
"Patients should find out whether they have cancer or not within 28 days of being referred for tests from April, under a new NHS target." https://bit.ly/37KCIFI #lungcancerscreening #lungscreening #lungcancer
Progress made in #lungcancer in the US, leading to the largest single-year drop in cancer deaths ever recorded. https://reut.rs/2sPIaZb #lungcancerscreening #lungscreening
We are so delighted to receive the #BioNewsRoundAward at #Genesis19. Incredibly proud of the Oncimmune team, the ECLS team for their support and most of all, our ECLS trial heroes who helped tell the story of the true impact EarlyCDT Lung can have on early #lungcancer detection.
Congratulations goes to the WINNER of this year’s #BioNewsRoundAward – @OncimmuneECDT!
Gallery
